CoChat

Anti-amyloid antibody therapies in Alzheimer's disease

Open access

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

After years of failed attempts to develop a disease-modifying therapy for Alzheimer’s disease, consistent evidence in support of clinical efficacy was finally presented for a monoclonal antibody targeting the amyloid-β protofibrils. In addition to meeting the primary outcome of slowing clinical disease progression over 18 months, secondary clinical outcomes and amyloid-β lowering on PET also underpin the positive results of the trial. In this opinion piece, we highlight the key characteristics of the previous unsuccessful trials and analyse the potential reasons why those attempts to develop a treatment for early Alzheimer’s disease failed. We compare the safety profiles of the different antibodies and highlight cautionary measures for their routine clinical use. Last, we discuss the role of blood-based biomarkers in transforming the clinical care pathway to facilitate the uptake of antibody treatments, proposing an integrated case-finding and treatment model crossing the different healthcare sectors. Taken together, a real breakthrough may have been achieved by proving that amyloid-β reduction results in clinical benefits, rather than just biomarker changes. At the same time, routine use of the new generation of drugs will show if statistical efficacy translates into clinically meaningful change. This may just be the beginning of a new era of Alzheimer’s disease drug development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awad005

Cites

39 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

Metadata

Authors
Perneczky, R., Jessen, F., Grimmer, T., Levin, J., Flöel, A., Peters, O., & Froelich, L.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • University of Cologne (DE)
  • TUM Klinikum (DE)
  • Universitätsmedizin Greifswald (DE)
  • Central Institute of Mental Health (DE)
Corresponding author
Perneczky, Robert
Venue
Brain
Published
2023-01-19
Volume
146
Issue
3
Pages
842-849
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W4317401758
Cited by
182
References
40
Citations by year
2026: 33 · 2025: 50 · 2024: 57 · 2023: 42
FWCI
32.13
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion)
  • PubMed (publishedVersion)
  • Open access LMU (Ludwid Maxmilian's Universitat Munchen) (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • DZNE Pub (submittedVersion)
Funders
  • Deutsche Forschungsgemeinschaft
  • VERUM Foundation
  • Sheffield National Institute for Health Research
  • Biomedical Research Centre
  • University of Cambridge—Ludwig-Maximilians-University Munich Strategic Partnership
  • Hector II Foundation
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, anti-amyloid monoclonal antibodies, amyloid-beta protofibrils, amyloid PET, disease-modifying therapy, clinical trial failure, antibody safety, blood-based biomarkers, case finding, early Alzheimer's disease
MeSH terms
Alzheimer Disease, Amyloid, Antibodies, Monoclonal, Humans, Biomarkers, Amyloid beta-Peptides, Treatment Outcome, Disease Progression, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.